- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06768723
Effects of Post-activation Performance Enhancement Protocols on Judo-specific Performance: a Randomized Crossover Trial
January 14, 2025 updated by: Universidade do Porto
Effects of Post-activation Performance Enhancement Protocols Using Upper-body, Lower-body, or Combined Upper- and Lower-body Exercises on Judo-specific Performance: a Randomized Crossover Trial
The study aimed to investigate the post-activation performance enhancement (PAPE) of the special judo fitness test (SJFT) of youth judo athletes using upper-body (isometric push-ups), lower-body (standing broad jumps), or their combination as conditioning exercise (CE).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Fourteen females (aged 16.5 ± 0.8 yrs) and nine males (aged 17.0 ± 0.9 yrs) performed the three CEs or a control condition (i.e., judo-specific warm-up) in a randomized crossover method.
The SJFT was conducted one minute after the CE or control condition.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Porto, Portugal, 4200-450
- Faculty of Sport of the University of Porto
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Minimum of 4 years of judo training and competition experience.
- Actively practicing the sport and preparing for a competition during the time of data collection
- Proficient at performing the ippon seoi-nage throwing (judo) technique
Exclusion Criteria:
- Disease or serious injury that inhibited participating in the warm-up protocols and subsequent testing sessions.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Upper body PAPE protocol
Half of the judo-specific protocol + 3 sets of 10-second hold isometric push-ups.
|
Assess which intervention delivered the best acute performance enhancements.
|
|
Experimental: Lower body PAPE protocol
Half of the judo-specific protocol + 3 sets of 6 repetitions of standing broad jump.
|
Assess which intervention delivered the best acute performance enhancements.
|
|
Experimental: Combined (Upper body+Lower body) PAPE protocol
Half of the judo-specific protocol + 3 sets of 3 repetitions of standing broad jump + 3 sets of 5-second hold isometric push-ups.
|
Assess which intervention delivered the best acute performance enhancements.
|
|
Active Comparator: Control (judo-specific) protocol
Judo-specific exercises that included 10 repetitions of ukemi drills (i.e., front, back, side, and rolling), 2 sets of 10 repetitions of "rapid" uchikomi drills (i.e., throwing drills), 2 sets of 1 minute of kumikata fight (i.e., grip fight), and 2 sets of 10 repetitions of nagekomi (i.e., practice throws).
|
Assess which intervention delivered the best acute performance enhancements.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Special judo fitness test (SJFT)
Time Frame: 15 seconds for the 1st set, 30 seconds for sets #2 and #3
|
Three sets of time-limited judo throws, assessing the number of throws
|
15 seconds for the 1st set, 30 seconds for sets #2 and #3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: During the SJFT, immediately after the SJFT, and 1 minute after the SJFT
|
Monitoring of heart rate
|
During the SJFT, immediately after the SJFT, and 1 minute after the SJFT
|
|
Rate of perceived exertion
Time Frame: 30 minutes after each testing session
|
Assess perceived exertion
|
30 minutes after each testing session
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: José Afonso, Ph.D., Faculty of Sport of the University of Porto
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2023
Primary Completion (Actual)
October 20, 2023
Study Completion (Actual)
October 20, 2023
Study Registration Dates
First Submitted
January 6, 2025
First Submitted That Met QC Criteria
January 6, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 14, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymised data pertaining sample characteristics and results of the implemented assessments will be shared upon request.
IPD Sharing Time Frame
Anonymised data pertaining sample characteristics and results of the implemented assessments will be shared upon request.
No predicted end date.
IPD Sharing Access Criteria
Anonymised data pertaining sample characteristics and results of the implemented assessments will be shared upon request.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.